pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma
Celgene
Celgene Europe Limited
Celgene Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Relapsed or Refractory Multiple Myeloma (RRMM), Relapsed and/or Refractory Multiple Myeloma, Multiple Myeloma, Moderate
Summit, USA HQ
2,104 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 2,104
- Programs
- 45
- Drugs
- 91
- Patents
- 0
RPC01-3203
Phase 3 · small molecule · Moderately to Severely Active Crohn's Disease
RPC01-3203 for Moderately to Severely Active Crohn's Disease is a Phase 3 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Internal code RPC01-3203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Celgene Europe Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Moderately to Severely Active Crohn's Disease
- Status
- active
- Trials
- 1